![Richard E. Gammans](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard E. Gammans
Presidente en Pamlico BioPharma, Inc. .
Cargos activos de Richard E. Gammans
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Pamlico BioPharma, Inc.
![]() Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Director de Operaciones | - | - |
Presidente | - | - | |
Otologic Pharmaceutics, Inc.
![]() Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | Director de Operaciones | - | - |
Presidente | - | - |
Historial de carrera de Richard E. Gammans
Antiguos cargos conocidos de Richard E. Gammans.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MEDICINOVA, INC. | Corporate Officer/Principal | 01/06/2004 | 12/06/2009 |
Incara Pharmaceuticals Corp. | Director Técnico/Científico/I+D | 01/06/2000 | 09/08/2004 |
Indevus Pharmaceuticals, Inc.
![]() Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Director Técnico/Científico/I+D | 01/03/1994 | 01/05/2000 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Formación de Richard E. Gammans.
University of Georgia | Doctorate Degree |
Purdue University | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 9 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Graduate Degree | 2 |
Sectorial
Health Technology | 7 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
MEDICINOVA, INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Empresas privadas | 4 |
---|---|
Incara Pharmaceuticals Corp. | Health Technology |
Indevus Pharmaceuticals, Inc.
![]() Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Pamlico BioPharma, Inc.
![]() Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Health Technology |
Otologic Pharmaceutics, Inc.
![]() Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | Health Technology |
- Bolsa de valores
- Insiders
- Richard E. Gammans
- Experiencia